MEI Pharma, Inc. (MEIP) - 10-Q Summary
Business Context and Reporting Period
This filing covers the quarterly period ended September 30, 2024. MEI Pharma, Inc. is a pharmaceutical company developing cancer therapies. During the quarter, the company announced an evaluation of strategic alternatives, including a potential wind-down of operations. Consequently, the company discontinued the clinical development of its lead candidate, voruciclib, and initiated a reduction-in-force (RIF). Key executive changes included the departure of the CEO and CMO, with the CFO assuming the role of Acting CEO.
Key Financial Metrics
| Metric | Q3 2024 | Q3 2023 |
|---|---|---|
| Total Revenue | $0 | $65.3 million |
| Net Loss | $(8.0) million | $56.4 million (Income) |
| Operating Expenses | $8.4 million | $10.0 million |
| Cash & Short-Term Investments | $26.9 million | $38.0 million (approx.) |
| Net Cash Used in Operating Activities | $(11.5) million | $(18.5) million |
| Accumulated Deficit | $(396.2) million | $(349.6) million |
Note: Q3 2023 revenue included a one-time recognition of $64.5 million from the termination of a prior collaboration agreement.
Material Changes vs. Prior Period
- Revenue Collapse: Revenue dropped to zero from $65.3 million in the prior year. The prior year figure was driven by the recognition of deferred revenue upon the termination of the Kyowa Kirin (KKC) collaboration agreement. No such revenue was recognized in Q3 2024.
- Profitability Shift: The company swung from a net income of $56.4 million in Q3 2023 to a net loss of $8.0 million in Q3 2024, primarily due to the absence of the collaboration revenue.
- Expense Reduction: Operating expenses decreased by approximately $1.7 million year-over-year. Research and Development (R&D) expenses fell 9.2% to $3.2 million, and General and Administrative (G&A) expenses fell 20.5% to $5.2 million, reflecting the strategic wind-down and RIF.
- Liquidity: Cash and short-term investments decreased from approximately $38.3 million at the end of the prior fiscal year (June 30, 2024) to $26.9 million at September 30, 2024, due to operating losses and lease termination payments made in the prior quarter.
Outlook, Risks, and Unusual Items
- Strategic Alternatives: The Board is evaluating options including asset sales, mergers, or an orderly wind-down to maximize shareholder value. Clinical development of voruciclib has ceased.
- Subsequent Event - Asset Sale: On October 22, 2024, the company sold its rights to the drug candidate ME-344 to Aardvark Therapeutics, Inc. for an initial payment of $0.5 million plus reimbursement, with potential future milestones up to $62.0 million.
- Liquidity Risk: Management believes current cash and investments ($26.9 million) are sufficient to fund operations for at least the next 12 months. However, the company has an accumulated deficit of $396.2 million and expects to continue incurring losses.
- Lease Termination: The company terminated its San Diego office lease effective September 30, 2024, incurring a termination fee of approximately $11.1 million (paid in the prior quarter) and an impairment charge of $10.4 million (recorded in the prior fiscal year).
- Employee Termination: The company expects to incur up to $6.0 million in severance and retention costs related to the 2024 RIF.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $26.9 million cash balance against the projected burn rate during the strategic review period.
- ME-344 Sale Terms: Review the Asset Purchase Agreement details regarding the $62.0 million in potential milestone payments and the likelihood of their achievement.
- Severance Obligations: Monitor the actual costs incurred for the 2024 RIF against the estimated $6.0 million cap.
- Strategic Outcome: Track the timeline and results of the strategic alternatives process (sale, merger, or liquidation).
- Deferred Revenue: Confirm that no remaining deferred revenue exists from the terminated KKC agreement, as all was recognized in the prior fiscal year.